These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 14608195)

  • 1. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
    Terrill KR; Lemons RS; Goldsby RE
    J Pediatr Hematol Oncol; 2003 Nov; 25(11):864-7. PubMed ID: 14608195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer.
    Liu CY; Jain V; Shields AF; Heilbrun LK
    J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):39-44. PubMed ID: 14709685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial.
    Deitcher SR; Fesen MR; Kiproff PM; Hill PA; Li X; McCluskey ER; Semba CP;
    J Clin Oncol; 2002 Jan; 20(1):317-24. PubMed ID: 11773185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
    Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
    J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
    Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
    J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients.
    Ng R; Li X; Tu T; Semba CP
    J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):45-9. PubMed ID: 14709686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters.
    Chesler L; Feusner JH
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):653-6. PubMed ID: 12439038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
    Jacobs BR; Haygood M; Hingl J
    J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of reteplase in poorly functioning hemodialysis catheters.
    Falk A; Samson W; Uribarri J; Vassalotti JA
    Clin Nephrol; 2004 Jan; 61(1):47-53. PubMed ID: 14964457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
    Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
    J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of reteplase for thrombolysis of hemodialysis catheters at a community and academic regional medical center.
    Hyman G; England M; Kibede S; Lee P; Willets G
    Nephron Clin Pract; 2004; 96(2):c39-42. PubMed ID: 14988596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on reteplase in thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    BioDrugs; 2007; 21(1):65-8. PubMed ID: 17263591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reteplase: a review of its use in the management of thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    Am J Cardiovasc Drugs; 2006; 6(4):265-85. PubMed ID: 16913828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for restoring patency of occluded central venous catheter lumens.
    van Miert C; Hill R; Jones L
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD007119. PubMed ID: 22513946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reteplase for dysfunctional hemodialysis catheter clearance.
    Hilleman DE; Dunlay RW; Packard KA
    Pharmacotherapy; 2003 Feb; 23(2):137-41. PubMed ID: 12587800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
    Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
    Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system.
    Scott DM; Ling CY; MacQueen BC; Baer VL; Gerday E; Christensen RD
    J Perinatol; 2017 Mar; 37(3):291-295. PubMed ID: 27831547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.